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Background: Rhinoviruses (RVs) are a major cause of common colds and induce exacerbations of asthma and
chronic inﬂammatory lung diseases.
Methods:We expressed and puriﬁed recombinant RV coat proteins VP1-4, non-structural proteins as well as N-
terminal fragments of VP1 from four RV strains (RV14, 16, 89, C) covering the three known RV groups (RV-A, RV-
B and RV-C) and measured speciﬁc IgG-subclass-, IgA- and IgM-responses by ELISA in subjects with different
severities of asthma or without asthma before and after experimental infection with RV16.
Findings: Before infection subjects showed IgG1 N IgA N IgM N IgG3 cross-reactivity with N-terminal fragments
from the representative VP1 proteins of the three RV groups. Antibody levels were higher in the asthmatic
group as compared to the non-asthmatic subjects. Six weeks after infection with RV16, IgG1 antibodies showed
a group-speciﬁc increase towards the N-terminal VP1 fragment, but not towards other capsid and non-structural
proteins, which was highest in subjects with severe upper and lower respiratory symptoms.
Interpretation: Our results demonstrate that increases of antibodies towards the VP1 N-terminus are group-
speciﬁc and associated with severity of respiratory symptoms and suggest that it may be possible to develop se-
rological tests for identifying causative RV groups.© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Rhinoviruses (RVs) are the most common cause of respiratory
illnesses in children and adults of all ages and are responsible for
more than 50% of acute exacerbations of asthma and chronic
obstructive pulmonary disease (COPD) (Donaldson et al., 2003;
Johnston et al., 1995; Nicholson et al., 1993). Severe RV infections
during infancy have also been linked to the subsequent development
of asthma and the presence of rhinovirus in the lower airway to theive pulmonary disease; ICAM-1,
roteinreceptor;ICS, Inhaledcor-
expiratory ﬂow; MALDI–TOF,
ght mass spectrometry; ELISA,
eroxidase;O.D, Optical density;
n; TCID50, Tissue culture 50% in-
opathology, Department of
athophysiology, Infectiology
hringer Guertel 18-20, 1090
alenta).
. This is an open access article undercontribution to disease persistence and severity (Jackson et al.,
2008; Wos et al., 2008).
Additional support for the causal relationship between RV infections
and asthma exacerbations comes from studies in which asthmatic and
healthy individuals are subjected to experimental RV infections, in
particular using RV16 as a model strain. Using such infection studies it
has been demonstrated that RV infections increase airway hyper-
reactivity and late phase asthmatic responses (Lemanske et al., 1989).
Furthermore, experimental RV infection increases biological and physi-
ological markers indicative for asthma (Bardin et al., 2000; Grunberg
et al., 1997; Message et al., 2008). Interestingly, it was found that high
allergen-speciﬁc IgE levels increase the risk of rhinovirus-induced
wheezing and that rhinovirus infections increase asthmatic reactions
induced by subsequent allergen provocation providing possible links
between RV- and allergen-induced asthma (Calhoun et al., 1994;
Soto-Quiros et al., 2012).
Using RV89 as a model we discovered recently that IgG1 and IgA an-
tibodies of RV-infected individuals recognize primarily the N-terminal
portion of the rhinovirus capsid protein VP1 (Niespodziana et al.,
2012). The VP1-speciﬁc antibodies were also found to cross-reactthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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(Edlmayr et al., 2011; Iwasaki et al., 2013).
Currently, more than 100 RV serotypes have been described. They
are divided into two major species, RV-A and RV-B, based on the nucle-
otide sequences that encode VP1–VP4 capsid proteins (Kim and Gern,
2012). A newly classiﬁed third species, human rhinovirus C (RV-C)
was found to occur worldwide and seems to be more virulent than
other RVs (Bochkov and Gern, 2012). The majority of RV strains attach
to the cell by the intercellular adhesion molecule 1 (ICAM-1), whereas
a small number of serotypes use the low density lipoprotein receptor
(LDL-R) to gain entrance into human cells (Greve et al., 1989; Hofer
et al., 1994). The receptor for RV-C, however, has not yet been identiﬁed
(Arden et al., 2010).
In this study we expressed and puriﬁed the coat protein VP1 from
RV16, 89 (RV-A), 14 (RV-B) and C (RV-C) as well as the major epitope-
containing N-terminal portions of the VP1 proteins to compare the kinet-
ics, speciﬁcities andmagnitudes of antibody responses in individualswith
and without asthma after experimental RV16 infection. Our study re-
vealed that experimental RV infection induced a strain-speciﬁc boost of
antibody production against the N-terminal epitope on VP1 which was
associated with the severity of respiratory symptoms.2. Methods
2.1. Expression and Puriﬁcation of Recombinant RV Proteins and Fragments
Thereof, Peptide Synthesis
Amino acid sequences of structural (VP1-VP4) and non-structural
(2A, 2C, 3C, 3D) RV proteins from RV16, 14, 89 and C were obtained
from the National Center for Biotechnology Information database (Sup-
plemental Table 1: GenBank accession numbers). Complete genes or
fragments thereof with codon usages optimized for Escherichia coli
expression were synthesized with the addition of a DNA coding for a
hexahistidine tag at the 3′ end (Genscript, Piscataway, NJ, USA) and
cloned into either the NdeI/XhoI restriction sites of pET27b vector
(Novagen, Madison, WI, USA) or the EcoRI/HindIII restriction sites of
pMalC4X vector downstream of the malE gene of E. coli (New England
Biolabs, Ipswich, MA, USA) (Supplemental Table 1). DNA sequences of
the plasmid constructs were conﬁrmed by restriction enzyme analysis
of midi-prep plasmid DNA (Promega, Madison, WI, USA) and DNA se-
quencing (MWG Euroﬁns, Ebersberg., Germany).
Recombinant structural and non-structural proteins as well as MBP
fusion proteins containing VP1 fragments were expressed in E. coli
strain BL21 (DE3) (Stratagene, La Jolla, CA, USA). All proteinswere puri-
ﬁed by nickel afﬁnity chromatography under denaturing conditions
(Qiagen, Hilden, Germany) as described (Niespodziana et al., 2012).
The purity of recombinant proteins was analyzed by Coomassie-
stained SDS-PAGE and their identity was conﬁrmed by immunoblotting
using a monoclonal mouse anti-His-tag antibody 1:1000 diluted
(Dianova, Hamburg, Germany). Bound antibodies were detected with
1:1000 diluted alkaline phosphatase-coupled rat anti-mouse IgG anti-
bodies (BD Biosciences, Erembodegem, Belgium). Protein concentra-
tions were determined using BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc, Rockford, IL, USA).
The non-structural 3B protein from strain 89 (VPg: GPYSGEPKPK
SRAPERRVVTQ) was produced by solid phase peptide synthesis (CEM-
Liberty instrument, Matthews, NC; Applied Biosystems, Life technolo-
gies, Carlsbad, CA) with the 9-ﬂuorenyl-methoxy-carbonyl-method,
using a PEG-PS preloaded resin (Applied Biosystems, Carlsbad, CA,
USA). The peptide was puriﬁed by reversed-phase HPLC (Dionex Ulti-
Mate 3000 Pump, Sunnyvale, CA) using a Jupiter 4 μm Proteo 90 Å, LC
column (Phenomenex, Torrance, CA, USA) and a 10–70% acetonitrile
gradient. The masses of the recombinant proteins and of the synthetic
peptide were determined by mass spectrometry (Microﬂex, MALDI–
TOF, Bruker Daltonics, Billerica, MA).2.2. Patients, Experimental RV16 Infection
As previously reported (Beale et al., 2014; Jackson et al., 2014), infec-
tions with RV16 were induced in 28 asthmatic patients (11 with mild
asthma and 17 with moderate asthma (GINA., 2004)) and 11 healthy
adult individuals in a study approved by the ethical committee of the
Imperial College of London (09/H0712/59). Informed written consent
was obtained from all subjects. Only adults but no children participated
in the study. The healthy adult subjects were non-smoking, non-atopic
and non-asthmatic volunteers aged 21–55 years (4 females, 7 males).
Patients with mild asthma were aged 19–53 years (7 females, 4 males)
takingonly short-actingβ2 agonists (SABA). The patientswithmoderate
asthma, aged 20–54 years (8 females, 9 males) were on short acting
beta agonists (SABA) plus inhaled corticosteroid therapy. Two out of
17 moderate asthmatics were not on ICS therapy but met criteria for
moderate asthma. Total IgE levels weremeasured using ImmunoCAP
technology (Phadia/Thermoﬁsher, Uppsala, Sweden) (healthy: 14–
19 IU/ml, median: 16 IU/ml; mild asthmatics: 102–739 IU/ml, medi-
an: 207 IU/ml; moderate asthmatics: 66–368 IU/ml, median: 132 IU/
ml) (Beale et al., 2014; Dostaler et al., 2011). The baseline demographic
and clinical characteristics of the volunteers are described in (Beale et al.,
2014; Jackson et al., 2014). Experimental infectionwith RV16was induced
by using a 100 tissue culture 50% infective dose (100 TCID50) of RV16 on
day 0 by nasal spray as described (Message et al., 2008). Blood samples
were taken on day 0, 7, 14 and 42 days after infection. Respiratory symp-
toms were assessed by daily diary cards, from 2 weeks before baseline
sampling until 6 weeks post-inoculation as described (Message et al.,
2008). Total upper and lower respiratory scores were calculated by sum-
ming the corrected daily scores for the 2-week infection period. Healthy
individuals and asthmatic patients were grouped according to their total
upper and lower symptom scores (0–20, 21–40, N41). Anonymized
serum samples were analysed with the approval of the ethics committee
of the Medical University of Vienna, Austria (EK1721/2014).
2.3. ELISA Experiments
ELISA plates (Nunc, Langenselbold, Germany) were coated with
2 μg/ml of each of the tested proteins (recombinant structural-,
non-structural RV proteins, recombinant VP1 fragments, human
serum albumin HSA, maltose-binding protein). Human sera were di-
luted 1:100 for IgG1 and 1:50 for IgA, IgM, IgG2, IgG3 and IgG4. Bound
human antibodies were detected with monoclonal mouse anti-
human IgA, IgM, IgG1, IgG2, IgG4 (BD Pharmingen, San Diego, CA)
diluted 1:1000 and IgG3 (Sigma-Aldrich) diluted 1:5000 followed
by detection with horseradish peroxidase (HRP)-conjugated sheep
anti-mouse IgG antibodies (Amersham Bioscience, Freiburg,
Germany) diluted 1:2000. The optical density (O.D.) values corre-
sponding to the levels of antigen-speciﬁc antibodies were measured
at 405 and 490 nm in an ELISA reader (Dynatech, Denkendorf,
Germany). All measurements were performed as duplicates with a
variation of less than 5%. Plate-to-plate normalization was done by
including a control serum with established VP1-speciﬁc antibody
levels on each of the plates (Stern et al., 2007). The reactivity to
human serum albumin (HSA) determined for each of the patient's
serum was used as a negative control. O.D. values greater than the
double HSA value were considered positive (cut-off). No binding of
detection antibodies to coated antigens was observed when mea-
surements were performed without addition of patient's serum
(buffer control).
2.4. Statistical Analysis
Differences between antibody levels were assessed by Mann–Whit-
neyU orWilcoxon test using SPSS software. Values of p b 0.05were con-
sidered signiﬁcant.
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3.1. Production and Characterization of a Panel of Recombinant RV Capsid
Proteins, Fragments Thereof and non-Structural Proteins
The scheme in Fig. 1 shows that the rhinovirus genome encodes four
capsid proteins, designated VP1–VP4, and seven replication proteins
(2A: protease; 2B: membrane-associated protein; 2C: NTPase; 3A:
exact function is not known; 3B: protein primer for viral RNA synthesis;
3C: protease; 3D: polymerase). Supplemental Table 1 and supplemental
Fig. 1 summarize the recombinant and synthetic RV proteins which
were produced to monitor immune responses in patients whowere in-
oculated with RV16. Furthermore, to investigate cross-reactivity among
strains,we expressed andpuriﬁedVP1 proteins and their corresponding
100 aa-fragments from RV89, RV14 and RVC (Supplemental Table 1,
Supplemental Fig. 1). These proteins represent distinct rhinovirus
groups, RV-A (RV16, RV89), RV-B (RV14) and RV-C (RVC). VP1 from
RV89 showed a sequence identity of 63% with VP1 from RV16 whereas
the sequence identity of VP1 from RVC and VP1 from RV14 to VP1 from
RV16 was much lower (i.e., 44% and 38%, respectively). Likewise, PI_89
showed higher sequence identity to PI_16 (56%) than to PI_C (40%) and
PI_14 (25%) (Supplemental Fig. 2).
With the exception of 2B and 3A, the remaining replication proteins
of RV89 (2A, 2C, 3C, 3D) could be either expressed and puriﬁed in E. coli
or produced as synthetic peptide (3B) (Supplemental Table 1, Supple-
mental Fig. 1). Each of the recombinant proteins and the 3B peptide
was analysed by matrix-assisted laser desorption/ionization–time-of-
ﬂight mass spectrometry (MALDI–TOF) which conﬁrmed their identi-
ties and calculated masses (data not shown).3.2. Experimental RV16 Infection Boosts Mainly pre-Existing VP1-speciﬁc
Antibody Responses
In sera obtained on the day of virus inoculation (day 0), IgG1, IgA and
IgM antibodies speciﬁc for VP1 were found in each of the healthy and
asthmatic individuals (Fig. 2B) whereas IgG2, IgG3 and IgG4 levels
were very low (Supplemental Fig. 3). VP1-speciﬁc IgG1 levels were
higher in the asthmatic patients than in the healthy persons but this dif-
ference was not signiﬁcant. With the exception of VP2 which reacted
with IgG1 antibodies, we found no relevant antibody responses speciﬁc
for the other coat proteins (i.e., VP3, VP4) (Fig. 2B, Supplemental Fig. 3).
Next, we compared coat protein-speciﬁc antibody levels in sera ob-
tained at days 4, 7 and 42 with those from day 0. Compared to day 0, no
relevant changes of coat-protein-speciﬁc antibody reactivities were
noted at days 4 and 7 (data not shown). Increases of antibody levels
(ΔO.D. = O.D.Day 42–O.D.Day 0) compared to day 0 were only found in
blood samples obtained at day 42 for VP1-speciﬁc IgG1 and IgA antibody
levels (Fig. 2C). Interestingly, the increases of VP1-speciﬁc IgG1 were
signiﬁcantly higher in the group of moderate asthmatics compared to
the healthy subjects (Fig. 2C, *p b 0.05).1
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Fig. 1.Organization of the rhinovirus genome. Genes coding for the capsid (1A, 1B, 1C, 1D)
and replication proteins (2A, 2B, 2C, 3A, 3C and 3D) are indicated. The magniﬁcation
shows the genes coding for three VP1 fragments (PI, PII, PIII). 3′ and 5′ UTR (untranslated
regions) and the DNA coding for the peptide VPg 3B are also shown.Supplemental Fig. 4 shows that the study subjects mounted IgG1 re-
sponses against VP1 from RV89 and that the IgG1 antibodies towards
VP1 from RV89 have also increased upon infection. However, we did
not detect relevant IgG1 levels against any of the tested non-structural
proteins from RV89 including 2A, 2C, 3B (VPg), 3C, or 3D and there
was no relevant increase of IgG1 levels against these proteins upon RV
infection.
3.3. IgG1 Antibodies are Mainly Directed Against the N-Terminal VP1
Fragment and Upon RV Infection Increase Strongly Among IndividualsWith
More Severe Asthma
The epitope speciﬁcity of the VP1-speciﬁc antibodies was mapped
with three recombinant fragments, of which each comprised approxi-
mately one third of RV16 VP1 (PI-PIII_16, Fig. 1, Supplemental
Table 1). We found that the VP1-speciﬁc IgG1 responses were almost
exclusively directed against the N-terminal VP1 fragment in healthy as
well as asthmatic subjects (Fig. 3, upper panel). Also the increases of
VP1-speciﬁc IgG1 antibodies were due to reactivity against the N-
terminal fragment and there was no spreading of antibody reactivities
towards other VP1 epitopes (i.e., PII_16 or PIII_16 fragments) (Fig. 3,
lower panel). Again, rhinovirus infection boosted PI_16-speciﬁc IgG1
antibodies signiﬁcantly stronger in the group ofmoderate asthmatic pa-
tients compared to healthy individuals (Fig. 3, lower panel, **p b 0.01).
3.4. The Increase of Antibodies After Rhinovirus Infection is Group-Speciﬁc
Fig. 4A, left panel shows that there is reactivity of IgG1 antibodies
with VP1 proteins from RV89, RV14 and RVC in the healthy and asth-
matic patients at day 0. The IgG1 antibodies also recognized the N-
terminal fragments of the VP1 proteins from RV89, RV14 and RVC
(Fig. 4A, right panel) but did not react with the PII and PIII fragments
from the other strains (data not shown).
VP1 from RV14 showed the lowest degree of sequence identity with
VP1 from RV16 (i.e., 38%). VP1 from RV14 and PI_14 was better recog-
nized by the sera than the corresponding proteins from RVC at day 0
(Fig. 4A).
After infection at day 42, IgG1 responses increased strongest against
the VP1 from RV89 which had the highest degree of sequence identity
with VP1 fromRV16 followed byVP1 fromRVCwhichwas the sequence
next closely related whereas IgG1 responses to VP1 from RV14 with the
lowest sequence identity showed no relevant increases (Fig. 4B). The hi-
erarchy of increases was mirrored by the increases observed for the N-
terminal fragments of the VP1 proteins although the hierarchy of the
increases against VP1 and PI did not show statistical signiﬁcance. How-
ever, both the PI_89 baseline IgG1 levels as well as their increases upon
infection were signiﬁcantly higher in the moderate asthmatic group
compared to the healthy subjects (Fig. 4, right panels, *p b 0.05).
3.5. Increases of IgG1 Antibodies Towards the N-terminal VP1 Fragment are
Highest in Patients With Severe Upper and Lower Respiratory Symptoms
Fig. 5 shows the associations between the increases in PI_16-speciﬁc
IgG1 responses and subjects grouped according to upper and lower air-
way symptom scores recorded during infection.We found that patients
with upper as well as lower respiratory symptom scores above 41
showed signiﬁcantly higher increases (ΔO.D. = O.D.Day 42–O.D.Day 0)
of PI_16 IgG1 levels than subjects with symptoms scores up to 20
(*p b 0.05; **p b 0.01) (Fig. 5). A signiﬁcantly higher increase of
PI_16-speciﬁc IgG1was also found for subjectswith lower respiratory
symptom scores above 41 as compared to subjects with a symptom
score between 21 and 40 (*p b 0.05) (Fig. 5, right panel). Treatment
with steroids (i.e., moderate asthmatics) seemed to have inﬂuence on
the severity of lower respiratory symptoms and antibody increases in
only few cases (Fig. 5).
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Fig. 2. Antibody responses to recombinant RV16 capsid proteins in subjects inoculated with RV16. (A) Time course of experimental RV16 infection. Inoculation was done on day 0 and
serum samples were collected on days 0, 4, 7 and 42. (B) IgG1 and IgA responses to VP1, VP2, VP3, VP4, and HSA (human serum albumin) (y-axes: optical density values) are displayed
as box plots for healthy subjects (white bars: n= 11),mild (light grey bars: n=10) andmoderate asthmatics (dark grey bars: n= 16). Fifty % of the values arewithin the boxes and non-
outliers are between the bars. Lines within boxes indicate median values. (C) Increases of capsid protein-speciﬁc IgG1 and IgA antibody levels between day 0 and 42 are shown as in (B).
Signiﬁcant differences are indicated (*p b 0.05).
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Herewe investigated the antigen- and epitope-speciﬁcity, magnitude,
course and type of antibody responses following human experimental
RV16 infection. In order to study the antigen and epitope-speciﬁcity of an-
tibody responses we expressed and puriﬁed a panel of recombinant cap-
sid proteins and fragments thereof from four distantly related RV strains
which represented the three RV groups A, B and C as well as non-
structural proteins/peptides from group A. Blood samples obtained on
the day of RV inoculation (i.e., baseline) showed that the antibody re-
sponses of the analysed individuals were mainly directed against a N-
terminal fragment of the VP1 protein, whereas the other coat proteins
VP2-VP4 as well as the non-structural proteins showed no relevant reac-
tivity. The result obtained at baseline conﬁrmed our earlier ﬁnding that
the N-terminus of VP1 represents a major epitope of rhinovirus-speciﬁc
antibodies (Niespodziana et al., 2012). Furthermore, the antibodiesreacting with the VP1 N-terminal epitope belonged mainly to the IgG1
subclass and to the IgA class and showed cross-reactivity with the N-
terminal portions of VP1 from three distantly related rhinovirus strains
belonging to groups A, B and C. Among the individuals studied, the
highest antibody levels were directed to group A, represented by RV 16
and 89whichmay be due to the fact that these individuals were exposed
mainly to rhinovirus group A strains in the past. After the experimental
infection with a group A strain, RV16, we found that mainly group A-
speciﬁc antibody responses increased whereas antibody responses to
VP1 from groups B and C showed no (i.e., group B represented by
RV14) or low (group C) increases. A correlation between antibody levels
measured before and after inoculation (i.e., day 42) was observed (data
not shown). It thus seemed that a boosting of an already established im-
mune response had occurred which also lead to appearance of neutraliz-
ing activities in the sera (Jackson et al., 2014). The increases of antibody
responses thus seemed to follow the degree of sequence homology
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Fig. 3. IgG1 antibodies are focused towards the N-terminal VP1 fragment and increase after
infection. Shown are IgG1 levels (y-axis: optical density values) for day 0 (A) and increases
between days 0 and 42 (B) for the three VP1 fragments (PI_16, PII_16, PIII_16) and malt-
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possible to create diagnostic tests which may allow to discriminate
between infections with different rhinovirus groups/strains based on an-
tibody reactivity proﬁles towards VP1 epitopes from different rhinovirus
strains. Furthermore, the analysis of blood samples at different time
points after experimental inoculation showed that the increases of VP1-
speciﬁc antibodies were only detectable at day 42 after inoculation but
not at days 4 and 7 after infection indicating that a period of 6–8 weeks
and perhaps more is required for the detection of increases of
rhinovirus-induced antibody responses after infection. However, a de-
tailed analysis of the time course of the generation of RV-induced anti-
body response is still needed to determine the optimal time window for
antibody measurements. Another interesting observation was that in-
creases of IgG1 antibody responses towards the VP1 N-terminal epitope
were strongest in the group of subjects suffering from more severe
forms of asthma as compared to individuals withmild asthma or without
asthma. In this context, it is important to note that asthmatic individuals
were observed to be more susceptible to naturally occurring RV infection
than non-asthmatic subjects in that lower respiratory symptoms and
changes in peak expiratory ﬂow (PEF) were more severe and of longer
duration (Bardin et al., 2000; Corne et al., 2002; Message et al., 2008;
Zhu et al., 2014).When individuals were grouped according to the sever-
ity of upper and lower respiratory symptoms occurring after infection it
turned out that the increases of antibody responses towards the N-
terminus of VP1 were signiﬁcantly higher in the individuals with severeupper and lower respiratory symptoms indicating that the antibody in-
creases are related to the severity of respiratory symptoms. The ﬁnding
that individuals with more severe manifestations of respiratory symp-
toms showed the highest increases of VP1-speciﬁc antibodies may be
explained by their different susceptibility towards rhinovirus infections
and/or by amore severe infectionwith greater tissue damage in the respi-
ratory tract (Contoli et al., 2006; Wark et al., 2005). Since the N-terminus
of VP1 is reported to not contain receptor binding sites for RV, these anti-
bodies may be directed mainly against a non-neutralizing epitope and
therefore may not protect against rhinovirus infections. This may
explain that the individuals with more severe asthma despite mounting
high VP1-speciﬁc antibody levels at baseline were not protected.
In summary our results indicate that it may be possible to use the N-
terminal portions of VP1 from different rhinovirus strains to develop
serological tests for the identiﬁcation of rhinovirus groups/strains in-
volved in infection. Furthermore, the increases of antibody levels may
serve as surrogate markers for the severity of respiratory symptoms.
At present, assays for the detection of rhinovirus strains are based on
reverse transcription of viral RNA and DNA ampliﬁcation by PCR. Such
tests at best demonstrate the presence of certain rhinovirus strains in
the respiratory tract but cannot conﬁrm whether an infection with a
certain strain has indeed taken place because it does not showwhether
the immune system has responded. For example, it would be important
to obtain data demonstrating the role of RV-C in inducing asthma
attacks as demonstrated here for RV 16, a group A strain for vaccine de-
velopment. The fact that increases of VP1-speciﬁc antibodies appear late
and hence are not suitable for the diagnosis of an acute RV infectionmay
be considered as a possible limitation but on the other hand there are no
RV-speciﬁc acute therapies available. However, the advantages of sero-
logical tests for identifying the culprit rhinovirus strains are that they
are easy to perform and that they can be used for the retrospective anal-
ysis of serum samples collected in various asthma cohorts (Bousquet
et al., 2013). Ultimately serological tests may be helpful for identifying
the most common and clinically relevant rhinovirus strains involved
in asthma exacerbations and to investigate in cross-sectional studies
the possible role of rhinovirus infections in other respiratory diseases,
in different geographic populations and age groups including not only
children but also adults and elderly persons. Longitudinal studies will
allow to study possible variations of culprit rhinovirus strains and to
study their importance as potential vaccine components. In fact, a
very recent publication showed that recombinant RV-A, -B, and -C
capsid proteins were useful for the measurement strain-speciﬁc anti-
bodies in asthmatic children (Iwasaki et al., 2014). If serological tests in-
deed allow identifying the most common and clinically relevant
rhinovirus strains involved in respiratory diseases, this information
may help designing vaccines for rhinovirus infections so that the vac-
cines include the clinicallymost relevant strains. Once such vaccines be-
come available the tests will be useful to identify persons at risk of
experiencing rhinovirus-induced exacerbations of respiratory diseases
for vaccination.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2014.11.012.
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